In a move that is likely to bring relief to a huge number of breast cancer patients, Mumbai-based Alkem Oncology has recently announced the launch of the breast cancer drug, Palbociclib under the brand name, Palbo.

Palbo which contains Palbociclib, is recommended by the National Comprehensive Cancer Network (NCCN-2022) as a first-line treatment for individuals with metastatic breast cancer who have hormone receptor positive (HR +)/human epidermal growth factor receptor 2-negative (HER2-) status.

It is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and Central Drugs Standard Control Organisation (CDSCO) when used in conjunction with either Aromatase Inhibitor (AI) or Fulvestrant. Backed by in-house manufacturing, the launch of Palbo by Alkem endeavors to ensure the accessibility and affordability of a novel life-saving cancer drug for Indian breast cancer patients.

Palbo comes in capsule form in multiple dose strengths with varied pricing ranges, including 125mg at Rs 6125 for 21 capsules, 100mg at Rs 6062, and 75mg at Rs 6000 for 21 capsules.

Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer which helps in inhibiting cancer cell growth.